Anal carcinoma: FDG PET/CT in staging, response evaluation, and follow-up

Sachin S. Saboo, Katherine Zukotynski, Atul B. Shinagare, Katherine M. Krajewski, Nikhil Ramaiya

Research output: Contribution to journalReview article

25 Scopus citations

Abstract

The role of FDG PET/CT in anal cancer is becoming increasingly important. At the time of initial staging, FDG PET/CT can detect the primary site of disease more frequently than CT, is sensitive for nodal and metastatic spread and alters staging in a significant number of patients. Indeed, the NCCN guidelines for anal cancer published in April 2012 recommend FDG PET/CT for therapy planning. Metabolic activity of primary anal cancer at presentation is a potential biomarker for predicting prognosis, treatment response and survival. More intensely FDG-avid primary malignancy is associated with a higher incidence of disease spread. Metabolic response following chemoradiotherapy is associated with improved survival. The aim of this paper is to provide an up-to-date pictorial review of FDG PET/CT in anal cancer at the time of staging and to illustrate its utility for determining response to therapy and detecting recurrent disease.

Original languageEnglish (US)
Pages (from-to)728-735
Number of pages8
JournalAbdominal Imaging
Volume38
Issue number4
DOIs
StatePublished - Aug 1 2013

    Fingerprint

Keywords

  • Anal carcinoma
  • Diagnosis
  • F-FDG PET/CT
  • Staging
  • Treatment monitoring

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology
  • Radiology Nuclear Medicine and imaging
  • Gastroenterology
  • Urology

Cite this

Saboo, S. S., Zukotynski, K., Shinagare, A. B., Krajewski, K. M., & Ramaiya, N. (2013). Anal carcinoma: FDG PET/CT in staging, response evaluation, and follow-up. Abdominal Imaging, 38(4), 728-735. https://doi.org/10.1007/s00261-012-9958-3